Treatment of solid tumors with an antagonistic LILRB4 mAb or serum depletion of LILRB4 restored previously repressed antitumor T cell responses, further implicating a supportive role for LILRB4 in tumor development (72). Here, LILRB4 is linked to neoplasm.